BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

379 related articles for article (PubMed ID: 10037172)

  • 21. Inhibition of proliferation of estrogen receptor‑positive MCF‑7 human breast cancer cells by tamoxifen through c‑Jun transcription factors.
    Xu Y; Zou ST; Zhu R; Li W; Gu CW; Wei SH; Xie JM; Wu HR
    Mol Med Rep; 2013 Apr; 7(4):1283-7. PubMed ID: 23404426
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vivo anergized CD4+ T cells have defective expression and function of the activating protein-1 transcription factor.
    Sundstedt A; Dohlsten M
    J Immunol; 1998 Dec; 161(11):5930-6. PubMed ID: 9834073
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Estrogen receptor beta (ER beta) level but not its ER beta cx variant helps to predict tamoxifen resistance in breast cancer.
    Esslimani-Sahla M; Simony-Lafontaine J; Kramar A; Lavaill R; Mollevi C; Warner M; Gustafsson JA; Rochefort H
    Clin Cancer Res; 2004 Sep; 10(17):5769-76. PubMed ID: 15355905
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bidirectional cross talk between ERalpha and EGFR signalling pathways regulates tamoxifen-resistant growth.
    Britton DJ; Hutcheson IR; Knowlden JM; Barrow D; Giles M; McClelland RA; Gee JM; Nicholson RI
    Breast Cancer Res Treat; 2006 Mar; 96(2):131-46. PubMed ID: 16261397
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The cis decoy against the estrogen response element suppresses breast cancer cells via target disrupting c-fos not mitogen-activated protein kinase activity.
    Wang LH; Yang XY; Zhang X; Mihalic K; Xiao W; Farrar WL
    Cancer Res; 2003 May; 63(9):2046-51. PubMed ID: 12727818
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Cytotoxicity of tamoxifen and its principal metabolites in human breast cancer cell lines].
    Bachmann-Moisson N; Barberi-Heyob M; Merlin JL; Ledrich ML; Batt AM; Guillemin F
    Bull Cancer; 1996 Oct; 83(10):808-15. PubMed ID: 8952630
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hormone-refractory breast cancer remains sensitive to the antitumor activity of heat shock protein 90 inhibitors.
    Beliakoff J; Bagatell R; Paine-Murrieta G; Taylor CW; Lykkesfeldt AE; Whitesell L
    Clin Cancer Res; 2003 Oct; 9(13):4961-71. PubMed ID: 14581371
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phenyl N-tert-butylnitrone down-regulates interleukin-1 beta-stimulated matrix metalloproteinase-13 gene expression in human chondrocytes: suppression of c-Jun NH2-terminal kinase, p38-mitogen-activated protein kinase and activating protein-1.
    Ahmed S; Rahman A; Hasnain A; Goldberg VM; Haqqi TM
    J Pharmacol Exp Ther; 2003 Jun; 305(3):981-8. PubMed ID: 12626640
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tamoxifen-induced ER-alpha-SRC-3 interaction in HER2 positive human breast cancer; a possible mechanism for ER isoform specific recurrence.
    Mc Ilroy M; Fleming FJ; Buggy Y; Hill AD; Young LS
    Endocr Relat Cancer; 2006 Dec; 13(4):1135-45. PubMed ID: 17158759
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Transcriptional regulation of IL-8 by Staphylococcus aureus in human conjunctival cells involves activation of AP-1.
    Venza I; Cucinotta M; Caristi S; Mancuso G; Teti D
    Invest Ophthalmol Vis Sci; 2007 Jan; 48(1):270-6. PubMed ID: 17197543
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A peptide fragment of ependymin neurotrophic factor uses protein kinase C and the mitogen-activated protein kinase pathway to activate c-Jun N-terminal kinase and a functional AP-1 containing c-Jun and c-Fos proteins in mouse NB2a cells.
    Adams DS; Hasson B; Boyer-Boiteau A; El-Khishin A; Shashoua VE
    J Neurosci Res; 2003 May; 72(3):405-16. PubMed ID: 12692907
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Transcription factor c-Jun activation represses mdr-1 gene expression.
    Miao ZH; Ding J
    Cancer Res; 2003 Aug; 63(15):4527-32. PubMed ID: 12907627
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The inhibitory activity of a transdominant c-jun mutant fused to the ligand binding domain of the estrogen receptor.
    Kim S; Brown PH; Birrer MJ
    Oncogene; 1996 Mar; 12(5):1043-53. PubMed ID: 8649795
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Idoxifene antagonizes estradiol-dependent MCF-7 breast cancer xenograft growth through sustained induction of apoptosis.
    Johnston SR; Boeddinghaus IM; Riddler S; Haynes BP; Hardcastle IR; Rowlands M; Grimshaw R; Jarman M; Dowsett M
    Cancer Res; 1999 Aug; 59(15):3646-51. PubMed ID: 10446976
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An ER activity profile including ER, PR, Bcl-2 and IGF-IR may have potential as selection criterion for letrozole or tamoxifen treatment of patients with advanced breast cancer.
    Henriksen KL; Rasmussen BB; Lykkesfeldt AE; Møller S; Ejlertsen B; Mouridsen HT
    Acta Oncol; 2009; 48(4):522-31. PubMed ID: 19173092
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Activation of cJun NH2-terminal kinase/stress-activated protein kinase by insulin.
    Miller BS; Shankavaram UT; Horney MJ; Gore AC; Kurtz DT; Rosenzweig SA
    Biochemistry; 1996 Jul; 35(26):8769-75. PubMed ID: 8679641
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Oestrogen receptor-mediated modulation of the EGFR/MAPK pathway in tamoxifen-resistant MCF-7 cells.
    Hutcheson IR; Knowlden JM; Madden TA; Barrow D; Gee JM; Wakeling AE; Nicholson RI
    Breast Cancer Res Treat; 2003 Sep; 81(1):81-93. PubMed ID: 14531500
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Increased expression of enolase alpha in human breast cancer confers tamoxifen resistance in human breast cancer cells.
    Tu SH; Chang CC; Chen CS; Tam KW; Wang YJ; Lee CH; Lin HW; Cheng TC; Huang CS; Chu JS; Shih NY; Chen LC; Leu SJ; Ho YS; Wu CH
    Breast Cancer Res Treat; 2010 Jun; 121(3):539-53. PubMed ID: 19655245
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Binding analysis of the estrogen receptor to its specific DNA target site in human breast cancer.
    Foster BD; Cavener DR; Parl FF
    Cancer Res; 1991 Jul; 51(13):3405-10. PubMed ID: 2054780
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Oligonucleotide microarray analysis of estrogen receptor alpha-positive postmenopausal breast carcinomas: identification of HRPAP20 and TIMELESS as outstanding candidate markers to predict the response to tamoxifen.
    Tozlu-Kara S; Roux V; Andrieu C; Vendrell J; Vacher S; Lazar V; Spyratos F; Tubiana-Hulin M; Cohen P; Dessen P; Lidereau R; Bièche I
    J Mol Endocrinol; 2007 Oct; 39(4):305-18. PubMed ID: 17909269
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.